Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma

Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma

Background Merkel cell carcinoma (MCC) is an aggressive skin cancer associated with poor survival. Programmed cell death-1 (PD-1) pathway inhibitors have shown high rates of durable tumor regression compared with chemotherapy for MCC. The current study was undertaken to assess baseline and on-treatm...

Full description

Bibliographic Details
Main Authors: Erin Jensen, Evan J Lipson, Martin A Cheever, Adil Daud, Brent A Hanks, Shailender Bhatia, Thomas Olencki, Kari Kendra, Mizuho Kalabis, William H Sharfman, Ragini R Kudchadkar, Philip A Friedlander, Sunil A Reddy, Brian C Boulmay, Adam Riker, Melissa A Burgess, Candice Church, Tomoko Akaike, Michi M Shinohara, Bob Salim, Blanca Homet Moreno
Format: Article
Language:English
Published: BMJ Publishing Group 2021-04-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/4/e002478.full

Internet

https://jitc.bmj.com/content/9/4/e002478.full

Similar Items